Table 3: Effects of tocilizumab on atherogenic index and other lipid ratios.

Atherogenic indexStudy (ref), patients ( 𝑁 ), and lipid ratio’s

HigherEmery et al. [33] ( 𝑁 = 3 3 8 ) LDL/HDL;
Genovese et al. [34] ( 𝑁 = 8 0 3 ) TC/HDL, LDL/HDL;
Smolen et al. [39] ( 𝑁 = 4 1 8 ) TC/HDL

Neutral Kume et al. [21] ( 𝑁 = 2 2 ) TC/HDL;
Kawashiri et al. [36] ( 𝑁 = 1 9 ) TC/HDL, apoB/apoA-1;
Maini et al. [37] ( 𝑁 > 5 0 ) TC/HDL;

N.A.Jones et al. [35]; Schultz et al. [38]

N.A.: not assessed.